GSK is swooping in on all these disttressed companies w drugs targeting infectious agents they did spero late last year for an antibiotic for UTIs I don't think either of these in and of themselves will be that big but who knows. They did sell over 500M of augmentin last year, and have an internal candidate they will file soon for UTIs and GC, so it is easy enough to add a couple other agents to detail for their primary care sales force This is the low risk low return approach to pharma I guess
Market Data 
Markets 
AI
